Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 6/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5084490 | 0.90 | NPY2R (0.74) | NPY2RMAPTNPC1SMN1; SMN2RAB9A | |
| SCHEMBL5079992 | 0.88 | NPY2R (0.71) | NPY2RMAPTNPC1SMN1; SMN2RAB9A | |
| SCHEMBL5081598 | 0.88 | NPY2R (0.68) | NPY2RMAPTNPC1SMN1; SMN2RAB9A | |
| SCHEMBL5083788 | 0.87 | NPY2R (0.70) | NPY2RMAPTNPC1SMN1; SMN2RAB9A | |
| SCHEMBL5080912 | 0.85 | NPY2R (0.71) | NPY2RMAPTNPC1SMN1; SMN2RAB9A | |
| SCHEMBL5084525 | 0.84 | NPY2R (0.74) | NPY2RMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5080923 | 0.82 | NPY2R (0.74) | NPY2RMAPTNPC1SMN1; SMN2RAB9A | |
| SCHEMBL5079928 | 0.81 | NPY2R (1.00) | NPY2RMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL7600687 | 0.81 | NPY2R (0.77) | NPY2RMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL14590786 | 0.81 | ALDH1A1 (0.69) | NPY2RMAPTMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | claimed |
| EP-1948629-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-30 | — | — | EP | claimed |
| WO-2007053436-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | claimed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | claimed |
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | disclosed |
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | disclosed |
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | disclosed |
| EP-1948629-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007053436-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053436-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY5R, NPY4R | NPY2R 1/4885MAPT 4559/4885NPC1 3192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.